Table 2.

Clinical characteristics of ten NMOSD patients with MOG antibody and AQP4 antibody^a)

Patient	Onset age, year/sex	Disease Duration, year	No. of attacks	Phenotype	First attack site/EDSS	Severe visual disability	BS symptoms	EDSS at last flow-up	Brain MRI	Spinal MRI lesion	CSF OCB	Other serumauto-antibodies	Treatment
1	15/F	6	3	NMO	LETM+ON+Brain/7	Yes	No	6	Large MS-like lesions	C4-Conus	No	No	CS, AZA
2	36/F	6	8	LETM	LETM/8	No	No	7	Small MS-like lesions	T1-Conus	No	No	RTX
3	18/F	2	8	NMO	LETM+ON+Brain/8.5	Yes	Yes	8	Small lesions	MS-likeC1-Conus	No	Yes	Met, HCQ
4	60/F	4	6	NMO	LETM/8.5	Yes	No	8.5	Small MS-like lesions	C2-Conus	No	No	CS, AZA
5	49/F	2	3	NMO	LETM/7.5	Yes	No	5	Small MS-like lesion	C1-Conus	No	No	CS, AZA
6	33/F	4	6	NMO	ON+Brain/3	No	No	6	Large MS-like lesions	C3-Conus	Yes	No	CS, AZA
7	15/F	5	7	NMO	ON/1	Yes	No	9	ADEM-like lesions with enhancement	C1-Conus	No	No	CS, AZA
8	20/F	5	10	NMO	LETM+ON/6.5	Yes	No	9	ADEM-like lesions without enhancement	C1-Conus	No	No	CS, AZA
9	30/F	3	4	NMO	LETM/7.5	No	No	8.5	ADEM-like lesions without enhancement	C1-Conus	No	No	RTX
10	36/F	3	6	NMO	LETM/8	Yes	No	6	Small MS-like lesions	C1-T12	No	No	RTX

^a)RTX, Rituximab. IVIG, intravenous immunoglobulin. HCQ, Hydroxychloroquine. Met, Methotrexate. AZA, azathioprine. BS, brainstem. CS, oral corticosteroids. EDSS, Expanded disability status scale score. LETM, longitudinally extensive myelitis. NMO, neuromyelitis optica. NMOSD, neuromyelitis optica spectrum disorders. OCB, oligoclonal bands. ON, optic neuritis. MS, multiple sclerosis. ADEM, acute disseminated encephalomyelitis. Severe visual disability was defined as visual acuity of 0.1 or less in one or both eyes at last follow-up. Other serum autoantibodies include antinuclear antibodies, anti-Sjögren’s syndrome A antibodies, anti-Sjögren’s syndrome B antibodies, thyroglobulin antibodies, and thyroid peroxidase antibodies.